ArticleAnnals of surgical oncology2021
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG).
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
- Safety of Pre-Operative Radiotherapy Combined With Intraoperative Radiotherapy for Retroperitoneal Sarcoma.Journal of surgical oncology · 2026Article
- Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.Annals of surgical oncology · 2026Article
- Article
- Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy.Cancer medicine · 2025Review
- Prognostic factors in retroperitoneal liposarcoma after R0 resection: a study of age, histologic type, tumor stage, and differentiation grade.American journal of translational research · 2025Article
- Anesthetic managements, morbidities and mortalities in retroperitoneal sarcoma patients experiencing perioperative massive blood transfusion.Frontiers in oncology · 2024Article
- Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review.Frontiers in oncology · 2024Review
- Review
- Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.Annals of surgical oncology · 2023Article
- Association between centre volume and allocation to curative surgery and long-term survival for retroperitoneal sarcoma.BJS open · 2023Article
- Significant Predictors of Postoperative Morbidity After Radical Resection of Retroperitoneal Sarcoma in a Tertiary Center.Annals of surgical oncology · 2023Article
- ASO Author Reflections: Surgical Morbidity of Retroperitoneal Sarcoma.Annals of surgical oncology · 2023Article
- Staging Systems and Nomograms for Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Complex Vascular Resections for Retroperitoneal Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Morbidity and Mortality after Surgery for Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2022Review
- Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.Annals of surgical oncology · 2022Review
- Impact of time to first relapse on long-term outcome in adult retroperitoneal sarcoma patients after radical resection.International journal of clinical oncology · 2022Article
- Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.International journal of cancer · 2022Article
- Unplanned reoperation after resection of retroperitoneal sarcoma: experience based on a high-volume sarcoma center.World journal of surgical oncology · 2022Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
27 authors at 20 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate perioperative morbidity after surgery for first locally recurrent (LR1) retroperitoneal sarcoma (RPS). Data concerning the safety of resecting recurrent RPS are lacking.
methodsData were collected on all patients undergoing resection of RPS-LR1 at 22 Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) centers from 2002 to 2011. Uni- and multivariable logistic models were fitted to study the association between major (Clavien-Dindo grade ≥ 3) complications and patient/surgery characteristics as well as outcome. The resected organ score, a method of standardizing the number of organs resected, as previously described by the TARPSWG, was used.
resultsThe 681 patients in this study had a median age of 59 years, and 51.8% were female. The most common histologic subtype was de-differentiated liposarcoma (43%), the median resected organ score was 1, and 83.3% of the patients achieved an R0 or R1 resection. Major complications occurred for 16% of the patients, and the 90-day mortality rate was 0.4%. In the multivariable analysis, a transfusion requirement was found to be a significant predictor of major complications (p < 0.001) and worse overall survival (OS) (p = 0.010). However, having a major complication was not associated with a worse OS or a higher incidence of local recurrence or distant metastasis.
conclusionsA surgical approach to recurrent RPS is relatively safe and comparable with primary RPS in terms of complications and postoperative mortality when performed at specialized sarcoma centers. Because alternative effective therapies still are lacking, when indicated, resection of a recurrent RPS is a reasonable option. Every effort should be made to minimize the need for blood transfusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.